Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Income for 10 consecutive years, with -$128.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 4.21% to -$128.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$575.0 million, a 0.88% decrease, with the full-year FY2025 number at -$575.0 million, down 0.88% from a year prior.
  • Net Income was -$128.6 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$73.0 million in Q3 2021 to a low of -$245.1 million in Q3 2022.
  • A 5-year average of -$145.8 million and a median of -$143.6 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 583.62% in 2021, then skyrocketed 34.87% in 2023.
  • Ultragenyx Pharmaceutical's Net Income stood at -$124.8 million in 2021, then decreased by 21.67% to -$151.8 million in 2022, then increased by 18.63% to -$123.6 million in 2023, then decreased by 8.62% to -$134.2 million in 2024, then rose by 4.21% to -$128.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Income are -$128.6 million (Q4 2025), -$180.4 million (Q3 2025), and -$115.0 million (Q2 2025).